News about VHIO

New study validates the prognostic value of the HER2DX test in HER2-positive breast cancer

Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1

Research June 5 2022 2022-06-07

A new treatment is effective for advanced HER2-low breast cancer

Treatment with trastuzumab deruxtecan, a combination of a targeted therapy with chemotherapy, increases progression-free survival of the disease and1

Research January 25 2022 2022-01-25

Developed the first genomic test for personalized HER2+ breast cancer treatments

The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.

Institutional September 18 2020 2020-09-22

Spin-off Reveal Genomics born to develop innovative diagnostic tests in oncology

Reveal Genomics’ first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.

News about VHIO

New study validates the prognostic value of the HER2DX test in HER2-positive breast cancer

A new treatment is effective for advanced HER2-low breast cancer

Developed the first genomic test for personalized HER2+ breast cancer treatments

Spin-off Reveal Genomics born to develop innovative diagnostic tests in oncology

Subscribe to the Newsletter of Clínic